Table 3. Characteristics of patients and indications for IN dexmedetomidine use.
| Variables | AABR (n=12) | CT (n=30) | DMSA (n=4) | MAG3 (n=3) | MRI (n=56) | P value |
|---|---|---|---|---|---|---|
| Age (months)† | 20.0 (10.5–26.0) | 22.0 (12.0–35.0) | 8 (5.5–12) | 48 (4–83) | 18.5 (8.5–40) | 0.271 |
| Weight (kg)† | 9.2 (8.4–10.8) | 11.8 (9.9–14.0) | 10.8 (9.5–12.3) | 16.7 (7.8–19.7) | 10.5 (7.8–13.9) | 0.479 |
| Male, n (%) | 7 (58.3) | 17 (56.7) | 1 (25.0) | 3 (100.0) | 34 (60.7) | 0.650 |
| Sedation success, n (%) | 10 (83.3) | 25 (83.3) | 3 (75.0) | 3 (100.0) | 19 (33.9) | <0.001* |
*, P value <0.05; †, median (interquartile range). AABR, automated auditory brainstem response; CT, computerized tomography; DMSA, dimercaptosuccinic acid renal scan; MAG3, mercaptoacetyltriglycine 3 renogram; MRI, Magnetic resonance imaging.